CIDRAP – The new bivalent (two-strain) Moderna COVID-19 vaccine booster triggered stronger neutralizing antibody responses against the highly transmissible Omicron variant at 28 days than the previously authorized booster, with no safety concerns, according to the interim results of a phase 2/3 open-label, nonrandomized study published late last week in the New England Journal of Medicine.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.